ArticleJournal of molecular modeling2026
Identification of potential inhibitors of dengue virus ns5 methyltransferase and polymerase domains through virtual screening and molecular dynamics studies.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Target, silence, replace: a review on RNA-based drugs in modern medicine.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
contextThe dengue virus continues to pose a serious global health challenge due to the absence of effective antiviral therapies. Non-structural protein 5 (NS5), a multifunctional non-structural protein containing methyltransferase and RNA-dependent RNA polymerase domains, is essential for viral replication and represents a high-priority therapeutic target. In this study, potential inhibitors targeting two functional sites of Dengue virus serotype 3 (DENV-3) NS5 were identified through structure-based virtual screening and structural dynamics analysis. Docking results identified PubChem compound 135,625,223 as the strongest binder at the RNA-binding site with a binding affinity of - 11.8 kcal/mol, forming a hydrogen bond with Arg
methodsThe full-length NS5 structure was constructed using homology modeling with MODELLER, ab initio modeling, and AlphaFold, and the best model was selected based on low RMSD and stereochemical quality. A library of 587 antiviral compounds retrieved from PubChem was docked against the SAM-binding site of the methyltransferase domain and the RNA-binding site of the polymerase domain using AutoDock Vina. The top-ranked ligands were further evaluated through Insilico screening and 300-ns molecular dynamics simulations using GROMACS.
Indexed as
Identifiers
42418067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.